Cramer’s ASCO Biotech Stocks (CELG, ONXX, WMT)

Posted: June 4, 2007 at 1:49 pm

On today’s Stop Trading segment on CNBC, Jim Cramer said he was shocked that Revlimid from Celgene (CELG) was hardly noticed and he thinks it’s ready to run here.  This down move in Celgene is a mistake.  He’s sticking with his Onyx Pharmaceuticals Inc. (ONXX) after they gave positive data at the American Society of Clinical Onclogy ("ASCO") after the company extended the life of liver cancer patients. 

Cramer said he’d still buy Wal-Mart (WMT-NYSE) here even after the run from the news Friday and after the upgrades today. 

Jon C. Ogg
June 4, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Read more: Cramer, ,
    • Featured Article:

    The 15 CEOs Who Should Be Paid $1 A Year

    Lee Iacocca, Chrysler’s CEO in 1979, worked for $1 a year while his company paid back taxpayers $1.2 billion in loan guarantees. Edward Liddy, former CEO of Allstate (ALL) was paid $1 a year when he stepped in to run the crumbling AIG (AIG) as the request of Henry Paulson, who was Treasury Secretary at [...]

    Read Full Story »
    Pages: 1 2 3 4